SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened activity following a quarterly earnings report that beat consensus estimates, driven by record revenue growth and accelerating AI infrastructure demand. While the community is actively debating the stock's long-term trajectory and the impact of its ambitious capital expenditure plans, market participants are also closely watching broader sector volatility and geopolitical tensions that are fueling debate over valuation corrections.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing extreme volatility and heavy selling pressure as investors react to disappointing earnings and concerns over massive capital expenditure for unproven AI and robotics projects. While the community is deeply polarized, many are debating the stock's long-term valuation versus the potential for a technical bounce, with some traders highlighting aggressive institutional flow and short-covering activity near support levels.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania Trump crypto token is currently generating significant social media volume, driven largely by intense criticism regarding the Trump family's involvement in various crypto ventures and accusations of a pump-and-dump scheme. The community remains deeply polarized, with active discussions focusing on the coin's drastic loss in value and its broader association with political grifting and market manipulation.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile is drawing intense investor attention as it faces high-stakes earnings, with market participants closely weighing the stock's fundamental growth against competitive pressures from satellite-based rivals like Starlink. The community is actively debating whether current price levels represent a generational buying opportunity or an overvalued position, while simultaneously tracking potential M&A speculation and infrastructure-level pivots toward AI and satellite-integrated connectivity.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom (AVGO) is trending as investors focus on its critical role in the AI infrastructure buildout, specifically its custom silicon partnerships with major hyperscalers like Google, Meta, and Apple. The community remains actively split between bullish sentiment fueled by strong long-term AI demand and CapEx spending, and caution surrounding broader semiconductor volatility, short-term earnings sensitivity, and geopolitical headwinds.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently a major focus of investor debate following its latest earnings, with the community polarized between those betting on the company's long-term potential in solid-state batteries for EVs and AI data centers, and those frustrated by the lack of near-term revenue and recent revisions to Volkswagen funding milestones. While some investors view the stock's recent price weakness as an accumulation opportunity ahead of future scaling, others are actively shorting the ticker due to skepticism regarding leadership's ability to transition from development to mass production.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow Inc. (NOW) is seeing intense community debate following a double-beat earnings report that highlighted over $1 billion in AI-related annual contract value, yet the stock price has experienced significant volatility due to broader market turbulence and concerns over rising AI-driven operational costs. Investors remain polarized, with many viewing the pullbacks as a generational buying opportunity based on strong enterprise demand and a 98% renewal rate, while skeptics warn of potential margin pressure and a broader shift in enterprise software sentiment.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently in the spotlight following a multi-year $1.5 billion strategic partnership with Amkor Technology to expand domestic advanced semiconductor packaging capabilities for next-generation AI platforms. While the company sees sustained infrastructure demand, investors remain focused on the broader semiconductor sector's volatility and the complex relationship between hyperscaler capital expenditure spending and long-term valuation.

ExxonMobil is an international oil and gas company, providing energy that helps underpin growing economies and improve living standards around the world. It uses innovation and technology to deliver energy to a growing world. The company explores for, produces, and sells crude oil, natural gas and petroleum products.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxon Mobil is trending as investors weigh volatile energy supply dynamics and geopolitical tensions against the company's strong free cash flow and potential long-term consolidation opportunities. The community remains divided, with active discussions focused on whether recent price fluctuations reflect a cooling of regional conflicts or simply market manipulation, while bulls continue to highlight the stock's role as a high-conviction dividend and inflation hedge.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron ($CVX) is trending as investor focus intensifies on energy infrastructure, fueled by a 20-year power deal with Microsoft to supply natural gas to a West Texas data center and persistent supply concerns surrounding the Strait of Hormuz. The community remains heavily divided, with some investors accumulating shares as a long-term hedge against energy scarcity and dividends, while others express frustration over the stock's price action failing to keep pace with broader crude oil momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS My final DD before the readout. A tour through how GPS was built, from the first mouse experiments to where we stand now. Bench research was never my thing, but this decades long story is pretty incredible and had to start somewhere.  
 
The initial wall: Why WT1 was considered almost undruggable as a vaccine. 
 
WT1 (Wilms&#39; Tumor 1) is a transcription factor, a master control protein, that sits overexpressed in the vast majority of acute myeloid leukemia, and in mesothelioma, ovarian, and other cancers. In 2009 a National Cancer Institute panel ranked 75 cancer antigens by how good a target each would make. WT1 came in first. Number 1 out of 75. 
 
So why did it take decades to build a vaccine against the best target in oncology? Because WT1 is a self-antigen, an &quot;oncofetal&quot; protein your own healthy cells express at low levels. Your immune system is trained during development to tolerate self. T-cells that react too strongly to your own proteins get deleted before they ever reach your bloodstream. So the T-cells that can see WT1 tend to be low-avidity, weak binders, the leftovers that slipped through tolerance. Vaccinating with plain WT1 mostly wakes up that weak, tired &quot;army&quot;. That&#39;s the wall. It&#39;s the same wall Stimuvax (MUC1) and MAGE-A3 crashed into, you can&#39;t rally a strong army against a target the army was built to protect. 
 
The first proof it could even work: the Japanese mouse experiments. 
 
Before GPS existed, the foundational question was simply: can you immunize against WT1 at all without the immune system attacking the body&#39;s own healthy WT1-expressing tissue? The answer came largely from Japanese groups (Sugiyama and colleagues, PMID 12188920). 
 
They immunized mice with WT1 peptides, then challenged them with WT1-expressing tumors. The vaccinated mice rejected the tumors, and survived, with no signs of auto-aggression against their normal organs that physiologically express WT1. That last clause is the whole ballgame for safety: the immune system could be pointed at WT1 on cancer without turning on the kidneys, marrow, and other tissues that also carry it. That preclinical result, tumor rejection without autoimmunity, is the reason a WT1 vaccine was worth pursuing in humans at all, and it foreshadows the clean safety profile GPS has carried through every trial since. 
 
The MSK insight: don&#39;t use the real target, use a sharpened decoy. 
 
Here&#39;s where Dr. David Scheinberg&#39;s group at Memorial Sloan Kettering enters. Their move was borrowed from their own earlier work on a different cancer target, bcr-abl in CML, where they&#39;d already shown you could vaccinate with native AND modified (&quot;heteroclitic&quot;) peptides. They ported that strategy to WT1 (Pinilla-Ibarz et al., Leukemia 2006, &quot;Improved human T-cell responses against synthetic HLA-A0201 analog peptides derived from the WT1 oncoprotein&quot; PMID 16990779). 
 
The concept: take the WT1 peptide and substitute a single amino acid at the &quot;anchor&quot; position, the spot that plugs into the HLA groove your cells use to display the peptide to T-cells. The right substitution makes the peptide bind the HLA groove more tightly and stably. A more stable, longer-displayed peptide is a louder alarm. It recruits stronger, higher-avidity T-cells than the native version ever could, and critically, those T-cells still cross-recognize the native WT1 on the actual tumor. You sharpen the decoy, and the response transfers to the real thing. 
 
The bench data, with the actual numbers. 
 
This is the study that shows the trick works. May, Dao, Pinilla-Ibarz, Maslak, Scheinberg et al., Clinical Cancer Research 2007 (PMID 17671141): &quot;Peptide Epitopes from the Wilms&#39; Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells.&quot; 
 
They ran a classic 51-chromium release cytotoxicity assay, radiolabel the tumor cells, add the T-cells, measure how much label gets released as cells are killed, against a WT1-positive human tumor line (JMN) and a WT1-negative control line (MeWo). The result: 
 
T-cells raised on the native WT1-A peptide: 19% lysis of the WT1-positive tumor vs 9.2% of the WT1-negative control. 
T-cells raised on the heteroclitic WT1-A1 analogue: 44.8% lysis of the WT1-positive tumor vs 22.2% of the control. P &lt; 0.001. 
 
Yup. The single-amino-acid modification more than doubled the tumor killing, from 19% to nearly 45%, while preserving specificity (it consistently killed WT1-positive cells harder than WT1-negative). That is direct, peer-reviewed, quantified proof that the core design choice does exactly what it was engineered to do.  
 
Why four peptides, and why that&#39;s the real innovation. 
 
A single killer-T-cell peptide, even a good one, tends to burn out. Immunology has a rule: durable, memory cytotoxic (CD8+ &quot;killer&quot;) responses require CD4+ &quot;helper&quot; T-cell support. This isn&#39;t a minor detail, it&#39;s arguably the lesson of the field. Earlier WT1 vaccine approaches that leaned on killer-cell epitopes without robust helper support repeatedly produced responses that were real but short-lived, strong for a few weeks, then fading, which is a leading explanation for why so many peptide vaccines generated measurable immune responses that never translated into clinical benefit. You can wake up the killers; the hard part is keeping them awake. 
 
GPS was built specifically to solve that. It contains four peptides: 
 
WT1-A1, a heteroclitic short peptide, the sharpened CD8+ killer trigger. 
 
WT1-331 and WT1-427, native long peptides that recruit CD4+ helper T-cells across many HLA types. 
 
WT1-122A1, a heteroclitic long peptide that stimulates both killers and helpers. 
 
The class-II helper epitopes were selected using the SYFPEITHI prediction algorithm for high binding affinity across many HLA-DRB1 molecules, deliberately, so the helper response works in a broad, genetically diverse patient population rather than only those with a lucky HLA type. That&#39;s why GPS is described as &quot;non-HLA-restricted.&quot; It&#39;s engineered breadth. 
 
And GPS&#39;s own Phase 2 immune monitoring suggests the design does what it was meant to: after six vaccinations, CD4+ helper T-cell responses were sustained through the vaccination period, with proliferation to the individual peptides rising 6- to 13-fold (p=0.008). The helper architecture, the piece earlier killer-only designs lacked, showed up and held. That&#39;s the durability bet, and in Phase 2 it cashed. 
 
The class-II helper epitopes were chosen using the SYFPEITHI prediction algorithm for high affinity across many HLA-DRB1 molecules, deliberately, so the vaccine works across a broad, genetically diverse patient population rather than only the lucky ones with the right HLA type. That&#39;s why GPS is described as &quot;non-HLA-restricted.&quot; It&#39;s engineered breadth, not luck. 
 
Proof it translates to humans. 
 
The next question is whether vaccinated patients actually generate these killers. They do. In the thoracic-cancer trial (Cancer Immunol Immunother, PMID 20532500), T-cells drawn from patients after vaccination killed WT1-positive tumor cells but not WT1-negative controls, and cytotoxicity was absent before vaccination and present after. The vaccine installed a killing capacity that wasn&#39;t there before. 
 
Then the AML Phase 2 (Maslak/Scheinberg, Blood Advances 2018): after 6 vaccinations, T-cell proliferation to the peptides rose 6- to 13-fold (p=0.008); 86% of tested HLA-A*02 patients mounted CD8 responses against the native WT1 (proving the decoy-to-real cross-reactivity held in patients); and the median overall survival in that CR1 cohort reached 67.6 months. Single-arm, so a signal rather than proof, but an extraordinary one. 
 
Why REGAL is the trial the FDA practically drew a map for. 
 
In 2011 the FDA published its only guidance dedicated to therapeutic cancer vaccines. Four core instructions: (1) treat in minimal residual disease, not bulky active cancer, because the immune response needs time and room; (2) use multiple antigens/epitopes to prevent tumor escape; (3) expect the survival curves to separate late, because immune memory builds slowly, and pick statistics accordingly; (4) use overall survival, not tumor response, as the endpoint. 
 
REGAL: enrolled in second remission (minimal disease). Four epitopes. Overall survival as the primary endpoint. And a pooled survival timeline that has stretched far past the original model, the exact late-emerging pattern the FDA said a working vaccine would produce. The failed vaccines of the 2000s violated those principles, single antigen, active disease, response endpoints. GPS reads like it was built from the guidance line by line, because the science underneath it was solving those exact problems a decade before the trial locked. 
 
Where we actually stand, honestly. 
 
Put the whole tour together. The #1-ranked target in cancer. A tolerance-breaking design proven at the bench to more than double tumor killing. Mouse data showing tumor rejection without autoimmunity. A four-peptide architecture built to fix the durability problem that sank earlier attempts. Cross-reactivity and killing confirmed in actual patients. A 67.6-month survival signal in Phase 2. And a Phase 3 designed almost exactly the way the FDA says these trials should be designed. 
 
The data is what decides. It always was. 
 
But this is not hope stacked on hope. This is fifteen-plus years of deliberate science, every design choice made to solve a specific problem that killed the vaccines before it, walking up to the finish line. If you ever wanted a front-row seat to the moment the field finds out whether the immune system can be taught to remember cancer, you have one. 
 
78 (79) of 80. Almost home team.

Geukinas

Rich_Strike

Sparta1013

stockphd

Duncan Teo

Ghost

Richard

Zain Tariq

Die Steppen Fuchs

gkhunis@yahoo.com

Groggok

KimJongTinyDong

Dude Manguy

10xorbust

Dwayne DeBardelaben

Rick Lee Taker

Long Johnson

upgrador

Troy Cumpston

Bla Bli Blu

Jay Glenn

Shawn Hawkins

_level_m_

상후니

Brandon Skelton

Jack

TTP222

CEOofstocks 🍁 ©️

StockTwits for iOS

Chris

StockTwits Web

Wei Bull

watcher334

$SLS 
@Stocktwits @tctranfo @StocktwitsHelp 
Could we get this important post below pinned to the Sellas board for the week ahead? Thanks.

OnTheBalance

Thor

Erika Malone

StockTwits For Android 

WeAreHydrogenHype

Space floopdop

$SLS Incredible post, and I wanted to add to this in regards to a study just from June 2026 for WT1 that I haven&#39;t seen anyone bring up yet, which is Hashi 2026 
 
I discovered it just a week ago.  While in pediatric AML and post-transplant, it is perhaps most compelling clinical evidence that WT1 vaccination translates immune response into survival benefit.   They achieved a 91% 3-Yr OS compared to the normal 40%. 
 
1) 17 pediatric patients with post-transplant AML received WT1 peptide vaccines for maintenance 
2) Primary endpoint met: 3-year OS of 70.6% (95% CI 43.1–86.6%), exceeding the 30% historical control benchmark 
3) 12 clinical responders (sustained CR at 1 year) had 3-year OS of 91.7% (95% CI 53.9–98.7%) 
4) Immune responders vs. non-responders: 3-year OS 90.9% vs. 40.0% (p=0.027) 
 
The low-burden remission setting and the heteroclitic modification works. Hashii used a heteroclitic WT1-235 peptide (M to Y), and it successfully induced WT1-specific CTLs that recognized the native WT1 epitope

Bruno Ferdinand

$SLS @LeftyMD BEST POST EVER, read this, sleep well, our time is coming. Thanks Lefty

Keith Thompson

AstaAzaria

$SLS Goat? 100%, Since you are lefty youbare messi. Yg can be CR7.

Reviewer

Sarah

@Scott2773 @HITTHEHOLE @MarketPro 

SLS The science behind the investment…lengthy, but a must read. 😎🏦

SteelerJon

bebrave

jhk35611

$SLS One should not post anything else here today out of respect for this great post!

Ehrenhardt

Peter

John Stewart

Tomilaaksonen

Steven G

$SLS Magnificent work—it commands admiration! It also reminds us why we are here. 
I have a question... are you suggesting that the vaccine is particularly effective in our case because it is used on patients with low WT1 expression (due to their remission status, and as explicitly recommended by the FDA)? So, we might be looking at a vaccine that isn&#39;t limited to AML in second complete remission (CR2), but could potentially become a universal, preventative treatment?    @LeftyMD

Ludo

$SLS outstanding dd 🎩 off &amp; thanks for all you share with us.

$SLS Can’t wait for tomorrow! And check out the greatest DD this board has ever seen!

Juhana Tikkanen

SELLAS Life Sciences Group Inc

 My final DD before the readout. A tour through how GPS was built, from the first mouse experiments to where we stand now. Bench research was never my thing, but this decades long story is pretty incredible and had to start somewhere.  
 
The initial wall: Why WT1 was considered almost undruggable as a vaccine. 
 
WT1 (Wilms' Tumor 1) is a transcription factor, a master control protein, that sits overexpressed in the vast majority of acute myeloid leukemia, and in mesothelioma, ovarian, and other cancers. In 2009 a National Cancer Institute panel ranked 75 cancer antigens by how good a target each would make. WT1 came in first. Number 1 out of 75. 
 
So why did it take decades to build a vaccine against the best target in oncology? Because WT1 is a self-antigen, an "oncofetal" protein your own healthy cells express at low levels. Your immune system is trained during development to tolerate self. T-cells that react too strongly to your own proteins get deleted before they ever reach your bloodstream. So the T-cells that can see WT1 tend to be low-avidity, weak binders, the leftovers that slipped through tolerance. Vaccinating with plain WT1 mostly wakes up that weak, tired "army". That's the wall. It's the same wall Stimuvax (MUC1) and MAGE-A3 crashed into, you can't rally a strong army against a target the army was built to protect. 
 
The first proof it could even work: the Japanese mouse experiments. 
 
Before GPS existed, the foundational question was simply: can you immunize against WT1 at all without the immune system attacking the body's own healthy WT1-expressing tissue? The answer came largely from Japanese groups (Sugiyama and colleagues, PMID 12188920). 
 
They immunized mice with WT1 peptides, then challenged them with WT1-expressing tumors. The vaccinated mice rejected the tumors, and survived, with no signs of auto-aggression against their normal organs that physiologically express WT1. That last clause is the whole ballgame for safety: the immune system could be pointed at WT1 on cancer without turning on the kidneys, marrow, and other tissues that also carry it. That preclinical result, tumor rejection without autoimmunity, is the reason a WT1 vaccine was worth pursuing in humans at all, and it foreshadows the clean safety profile GPS has carried through every trial since. 
 
The MSK insight: don't use the real target, use a sharpened decoy. 
 
Here's where Dr. David Scheinberg's group at Memorial Sloan Kettering enters. Their move was borrowed from their own earlier work on a different cancer target, bcr-abl in CML, where they'd already shown you could vaccinate with native AND modified ("heteroclitic") peptides. They ported that strategy to WT1 (Pinilla-Ibarz et al., Leukemia 2006, "Improved human T-cell responses against synthetic HLA-A0201 analog peptides derived from the WT1 oncoprotein" PMID 16990779). 
 
The concept: take the WT1 peptide and substitute a single amino acid at the "anchor" position, the spot that plugs into the HLA groove your cells use to display the peptide to T-cells. The right substitution makes the peptide bind the HLA groove more tightly and stably. A more stable, longer-displayed peptide is a louder alarm. It recruits stronger, higher-avidity T-cells than the native version ever could, and critically, those T-cells still cross-recognize the native WT1 on the actual tumor. You sharpen the decoy, and the response transfers to the real thing. 
 
The bench data, with the actual numbers. 
 
This is the study that shows the trick works. May, Dao, Pinilla-Ibarz, Maslak, Scheinberg et al., Clinical Cancer Research 2007 (PMID 17671141): "Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells." 
 
They ran a classic 51-chromium release cytotoxicity assay, radiolabel the tumor cells, add the T-cells, measure how much label gets released as cells are killed, against a WT1-positive human tumor line (JMN) and a WT1-negative control line (MeWo). The result: 
 
T-cells raised on the native WT1-A peptide: 19% lysis of the WT1-positive tumor vs 9.2% of the WT1-negative control. 
T-cells raised on the heteroclitic WT1-A1 analogue: 44.8% lysis of the WT1-positive tumor vs 22.2% of the control. P < 0.001. 
 
Yup. The single-amino-acid modification more than doubled the tumor killing, from 19% to nearly 45%, while preserving specificity (it consistently killed WT1-positive cells harder than WT1-negative). That is direct, peer-reviewed, quantified proof that the core design choice does exactly what it was engineered to do.  
 
Why four peptides, and why that's the real innovation. 
 
A single killer-T-cell peptide, even a good one, tends to burn out. Immunology has a rule: durable, memory cytotoxic (CD8+ "killer") responses require CD4+ "helper" T-cell support. This isn't a minor detail, it's arguably the lesson of the field. Earlier WT1 vaccine approaches that leaned on killer-cell epitopes without robust helper support repeatedly produced responses that were real but short-lived, strong for a few weeks, then fading, which is a leading explanation for why so many peptide vaccines generated measurable immune responses that never translated into clinical benefit. You can wake up the killers; the hard part is keeping them awake. 
 
GPS was built specifically to solve that. It contains four peptides: 
 
WT1-A1, a heteroclitic short peptide, the sharpened CD8+ killer trigger. 
 
WT1-331 and WT1-427, native long peptides that recruit CD4+ helper T-cells across many HLA types. 
 
WT1-122A1, a heteroclitic long peptide that stimulates both killers and helpers. 
 
The class-II helper epitopes were selected using the SYFPEITHI prediction algorithm for high binding affinity across many HLA-DRB1 molecules, deliberately, so the helper response works in a broad, genetically diverse patient population rather than only those with a lucky HLA type. That's why GPS is described as "non-HLA-restricted." It's engineered breadth. 
 
And GPS's own Phase 2 immune monitoring suggests the design does what it was meant to: after six vaccinations, CD4+ helper T-cell responses were sustained through the vaccination period, with proliferation to the individual peptides rising 6- to 13-fold (p=0.008). The helper architecture, the piece earlier killer-only designs lacked, showed up and held. That's the durability bet, and in Phase 2 it cashed. 
 
The class-II helper epitopes were chosen using the SYFPEITHI prediction algorithm for high affinity across many HLA-DRB1 molecules, deliberately, so the vaccine works across a broad, genetically diverse patient population rather than only the lucky ones with the right HLA type. That's why GPS is described as "non-HLA-restricted." It's engineered breadth, not luck. 
 
Proof it translates to humans. 
 
The next question is whether vaccinated patients actually generate these killers. They do. In the thoracic-cancer trial (Cancer Immunol Immunother, PMID 20532500), T-cells drawn from patients after vaccination killed WT1-positive tumor cells but not WT1-negative controls, and cytotoxicity was absent before vaccination and present after. The vaccine installed a killing capacity that wasn't there before. 
 
Then the AML Phase 2 (Maslak/Scheinberg, Blood Advances 2018): after 6 vaccinations, T-cell proliferation to the peptides rose 6- to 13-fold (p=0.008); 86% of tested HLA-A*02 patients mounted CD8 responses against the native WT1 (proving the decoy-to-real cross-reactivity held in patients); and the median overall survival in that CR1 cohort reached 67.6 months. Single-arm, so a signal rather than proof, but an extraordinary one. 
 
Why REGAL is the trial the FDA practically drew a map for. 
 
In 2011 the FDA published its only guidance dedicated to therapeutic cancer vaccines. Four core instructions: (1) treat in minimal residual disease, not bulky active cancer, because the immune response needs time and room; (2) use multiple antigens/epitopes to prevent tumor escape; (3) expect the survival curves to separate late, because immune memory builds slowly, and pick statistics accordingly; (4) use overall survival, not tumor response, as the endpoint. 
 
REGAL: enrolled in second remission (minimal disease). Four epitopes. Overall survival as the primary endpoint. And a pooled survival timeline that has stretched far past the original model, the exact late-emerging pattern the FDA said a working vaccine would produce. The failed vaccines of the 2000s violated those principles, single antigen, active disease, response endpoints. GPS reads like it was built from the guidance line by line, because the science underneath it was solving those exact problems a decade before the trial locked. 
 
Where we actually stand, honestly. 
 
Put the whole tour together. The #1-ranked target in cancer. A tolerance-breaking design proven at the bench to more than double tumor killing. Mouse data showing tumor rejection without autoimmunity. A four-peptide architecture built to fix the durability problem that sank earlier attempts. Cross-reactivity and killing confirmed in actual patients. A 67.6-month survival signal in Phase 2. And a Phase 3 designed almost exactly the way the FDA says these trials should be designed. 
 
The data is what decides. It always was. 
 
But this is not hope stacked on hope. This is fifteen-plus years of deliberate science, every design choice made to solve a specific problem that killed the vaccines before it, walking up to the finish line. If you ever wanted a front-row seat to the moment the field finds out whether the immune system can be taught to remember cancer, you have one. 
 
78 (79) of 80. Almost home team.

LeftyMD

@LeftyMD 🫡 Outstanding breakdown of the science. Most retail investors just chase the line on the chart, but understanding central tolerance and why the heteroclitic peptide design works is what separates real high-conviction longs from momentum traders. 

The shift from a simple killer T-cell trigger to adding CD4+ helper architecture is exactly why GPS didn’t suffer the same fate as Stimuvax. 

Excellent summary of the MSK research before the readout. Till Buyout 🥂

Droid

SoYeon

Muppet4k

Lonnie Konikoff

Jorge Lopes

Andy

EasyLode

Roger Rabbit $5,56

Allan Kristensen

Alex Vazquez

Kris Kotsay

Morten Balseth

MaXXIII X

Simon Sandalwood

Zschopower

Tomas

Jeff Freedman

LionTrader

Christopher W Meola

Shin

Cud Gel

Bob Lobla

John-Mark

Bercovici Adrian

 🫡 Outstanding breakdown of the science. Most retail investors just chase the line on the chart, but understanding central tolerance and why the heteroclitic peptide design works is what separates real high-conviction longs from momentum traders. 

The shift from a simple killer T-cell trigger to adding CD4+ helper architecture is exactly why GPS didn’t suffer the same fate as Stimuvax. 

Excellent summary of the MSK research before the readout. Till Buyout 🥂

@LeftyMD if Sterg is on this board incognito, he&#39;s Lefty.

Fitzgerald Davis

Saif Kareem

bikechain

LordKhaan

Rich

Anon

Sterg

Smikke2

Ian Carlin

Csaba Bagi

luca rapp

James Mckart

Kris

r smith

Nobody Special

 if Sterg is on this board incognito, he's Lefty.

Shultzy

Steve D

Bottsy

Peggy Murphy

Steve

semihound

Terry

Dave

Josh Szary

dozzer90

J Mattila

roger brugman

David Walters

@LeftyMD fantastic.  Thank you as always.

Nobody

Kiwi

nick

CAPRise

Russell Riley

Jesse

@LeftyMD brilliant - how did you pull all this together?

TraderMJ

avechristusrex_99

uhguy85

Cg526

Marty D Ford

 brilliant - how did you pull all this together?

stjernerogvann

@LeftyMD   You hit it out of the park again. Besides clearly explaining the complex immunology, you tied it to FDA guidance. Its a narrative that crushes the short thesis, however, be aware of one thing in the original paper that ranked tumor associated antigens, while WT1 was ranked first, the authors could not conclude that any antigen was perfect. We already know that Dr. Marc Reddish, a cancer vaccine expert gives GPS no chance. Of course his core argument is that the patients receiving BAT are healthier because of the higher lymphocyte count at baseline. My counter has been that he under estimates the cytopenias caused by BAT. If we stress test this post a little more, some bears will ask why Big Onc did not develop GPS sooner. My answer  here is several: The cancer vaccine graveyard, the shady history of GALE, that Big Onc&#39;s focus and capital spend easily can shift to newer mechanisms of action, and as u point out vaccines used when tumor was bulky.

Duane Nack